The hunt for a Huntington’s cure

Huntington’s disease and Friedreich’s ataxia are two debilitating diseases that progress to damage the nervous system and the brain over time. They are caused by parts of your DNA repeating themselves over and over again — kind of like a stuck record that gets worse the longer it plays.

Now scientists have found a way to sort those repetitive bits with a new type of gene-editing tool called base editing, rewriting single letters at a time in the DNA without cutting the entire strand.

Two types of base editors were used: cytosine and adenine.

The researchers tested the tools on mice and on cells of patients with Huntington’s or Friedreich’s ataxia and found that by changing just a few letters within the repeated DNA sections, they became more stable — preventing growth and ultimately more damage.

In mice, the brain remained more stable, and the worsening symptoms slowed.

While in its early stages, the research opens the door to potential treatments that don’t just mask symptoms — but could potentially tackle the disease at the fundamental level.

The article was published in Nature Genetics.

More like this: Spotting early signs of Alzheimer’s

New clues to spotting deadliest
prostate cancers

According to the American Cancer Society, one in eight men will be diagnosed with prostate cancer, and one in 44 will die from the disease. While the number of cases has drastically reduced in previous years, over 35,000 deaths still occur annually. Ongoing research into the prescreening and genetics of these patients is reducing deaths even more.

One of the most common and important modifiers, or chemical changes, in RNA molecules is m6A. When m6A is misregulated, it can cause abnormal cell growth, making cancers more aggressive and difficult to treat. As such, scientists are studying this as a potential target for cancer therapies.

A recent study published in Nature Genetics that mapped out the landscape of m6A in 162 primary prostate tumors revealed that m6A patterns are influenced by genetic mutations, tumor microenvironment and hypoxia.

The findings include that m6A dysregulation is linked to tumor growth and metastasis, in particular through modifications in genes like VCAN, which drives disease aggression and poor clinical outcomes.

This indicates m6A as a potential biomarker for prostate prognosis and treatment classes, opening new avenues for intervention and targeted therapeutics by showing how RNA changes, genes and environment influence prostate cancer.

More like this: A step forward in targeting tumors